Cars.com
CARS
Lantheus
LNTH
Halozyme Therapeutics
HALO
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
Collegium Pharmaceutical
COLL
(FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Nov 1, 2024 | (Q2)Aug 2, 2024 | (Q1)May 3, 2024 | (FY)Feb 2, 2024 | (Q4)Feb 2, 2024 | (Q3)Nov 3, 2023 | (Q2)Aug 4, 2023 | (Q1)May 5, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8.08%95.57B | 7.23%23.93B | 9.51%24.37B | 9.12%25.03B | 6.32%22.24B | -13.56%88.43B | -10.87%22.32B | -9.99%22.25B | -13.21%22.93B | 20.92B |
Operating revenue | 8.08%95.57B | 7.23%23.93B | 9.51%24.37B | 9.12%25.03B | 6.32%22.24B | -13.56%88.43B | -10.87%22.32B | -9.99%22.25B | -13.21%22.93B | --20.92B |
Cost of revenue | 10.01%74.32B | 7.36%18.25B | 11.44%19.06B | 12.36%19.72B | 9.65%17.44B | -15.15%67.56B | -11.83%17B | -10.05%17.1B | -16.39%17.55B | 15.9B |
Gross profit | 1.83%21.25B | 6.81%5.68B | 3.09%5.31B | -1.41%5.31B | -4.22%4.81B | -8.01%20.87B | -7.64%5.32B | -9.79%5.15B | -0.96%5.39B | 5.02B |
Operating expense | -4.12%15.01B | -8.00%3.52B | -0.63%3.64B | -5.99%3.97B | -1.60%3.89B | -7.43%15.66B | -16.25%3.83B | -7.17%3.66B | 1.27%4.22B | 3.95B |
Selling and administrative expenses | -7.04%11.95B | -11.68%2.75B | -2.56%2.89B | -9.33%3.19B | -4.23%3.12B | -9.05%12.86B | -17.58%3.11B | -9.12%2.97B | -0.73%3.52B | --3.26B |
Research and development costs | 9.28%3.06B | 7.96%773M | 7.66%745M | 10.64%780M | 10.90%763M | 0.79%2.8B | -9.94%716M | 2.22%692M | 12.62%705M | --688M |
Operating profit | 19.69%6.24B | 44.80%2.16B | 12.25%1.67B | 15.19%1.34B | -13.94%920M | -9.70%5.21B | 25.40%1.49B | -15.66%1.49B | -8.27%1.17B | 1.07B |
Net non-operating interest income expense | 4.11%-1.19B | 33.69%-187M | -3.17%-293M | 3.36%-345M | 3.79%-305M | -5.00%-1.24B | 13.23%-282M | -1.43%-284M | -13.69%-357M | -317M |
Non-operating interest income | ---- | ---- | -60.23%35M | -36.36%42M | -38.64%54M | 205.00%305M | 91.67%92M | 319.05%88M | 312.50%66M | --88M |
Non-operating interest expense | ---- | ---- | -11.83%328M | -8.51%387M | -11.36%359M | 20.61%1.55B | 0.27%374M | 23.59%372M | 28.18%423M | --405M |
Total other finance cost | --1.19B | --187M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other net income (expense) | 177.27%17M | 91.49%-8M | -44.68%-68M | 93.85%-84M | 33.90%79M | 97.86%-22M | 70.72%-94M | -47M | ||
Gain on sale of security | ---- | ---- | 177.27%17M | 91.49%-8M | -44.68%-68M | 67.73%-152M | 123.40%11M | 21.43%-22M | 70.72%-94M | ---47M |
Special income (charges) | ---- | ---- | ---- | ---- | ---- | 107.61%68M | ---- | ---- | ---- | ---- |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | -107.61%-68M | ---- | ---- | ---- | ---- |
-Gain on sale of business | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Income before tax | 29.87%5.05B | 53.11%1.97B | 17.97%1.39B | 38.52%989M | -22.41%547M | 20.53%3.89B | 39.54%1.29B | 159.91%1.18B | 12.44%714M | 705M |
Income tax | -31.79%472M | 238.46%440M | 50.57%265M | -42.86%148M | -421.26%-408M | -13.82%692M | -58.99%130M | -17.37%176M | 100.78%259M | 127M |
Net income | 43.22%4.58B | 32.30%1.53B | 12.25%1.13B | 84.84%841M | 65.22%955M | 31.92%3.2B | 91.09%1.16B | 316.60%1B | -10.08%455M | 578M |
Net income continuous Operations | 43.22%4.58B | 32.30%1.53B | 12.25%1.13B | 84.84%841M | 65.22%955M | 31.92%3.2B | 91.09%1.16B | 316.60%1B | -10.08%455M | --578M |
Net income discontinuous operations | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Minority interest income | 0.00%-16M | 50.00%-1M | -150.00%-5M | 28.57%-5M | 0.00%-5M | 20.00%-16M | 75.00%-2M | 50.00%-2M | -40.00%-7M | -5M |
Net income attributable to the parent company | 43.01%4.59B | 32.16%1.53B | 12.52%1.13B | 83.12%846M | 64.67%960M | 31.49%3.21B | 88.93%1.16B | 310.61%1.01B | -9.59%462M | 583M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 43.01%4.59B | 32.16%1.53B | 12.52%1.13B | 83.12%846M | 64.67%960M | 31.49%3.21B | 88.93%1.16B | 310.61%1.01B | -9.59%462M | 583M |
Basic earnings per share | 50.95%6.5816 | 33.79%2.1972 | 15.83%1.61 | 85.94%1.19 | 67.90%1.36 | 34.57%4.36 | 90.96%1.6423 | 308.82%1.39 | -7.25%0.64 | 0.81 |
Diluted earnings per share | 46.33%6.38 | 30.92%2.15 | 16.18%1.58 | 85.71%1.17 | 67.09%1.32 | 34.57%4.36 | 95.51%1.6423 | 312.12%1.36 | -7.35%0.63 | 0.79 |
Dividend per share | 20.27%1.78 | 20.27%0.445 | 20.27%0.445 | 20.27%0.445 | 20.27%0.445 | 12.12%1.48 | 12.12%0.37 | 12.12%0.37 | 12.12%0.37 | 0.37 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |